See more : Best Agrolife Limited (BESTAGRO.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Tarsus Pharmaceuticals, Inc. (TARS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tarsus Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Renovare Environmental, Inc. (RENO) Income Statement Analysis – Financial Results
- Nordic Iron Ore AB (publ) (NIO.ST) Income Statement Analysis – Financial Results
- SRM Energy Limited (SRMENERGY.BO) Income Statement Analysis – Financial Results
- JPMorgan Chase & Co. (0Q1F.L) Income Statement Analysis – Financial Results
- Tohoku Electric Power Company, Incorporated (TEPCY) Income Statement Analysis – Financial Results
Tarsus Pharmaceuticals, Inc. (TARS)
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 17.45M | 25.82M | 57.03M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.59M | 955.00K | 2.08M | 246.00K | 74.00K | 1.00K |
| Gross Profit | 15.85M | 24.86M | 54.95M | -246.00K | -74.00K | -1.00K |
| Gross Profit Ratio | 90.87% | 96.30% | 96.36% | 0.00% | 0.00% | 0.00% |
| Research & Development | 50.31M | 42.62M | 41.71M | 18.83M | 3.16M | 901.00K |
| General & Administrative | 0.00 | 44.95M | 25.40M | 8.17M | 1.14M | 449.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 108.70M | 44.95M | 25.40M | 8.17M | 1.14M | 449.00K |
| Other Expenses | 0.00 | 86.00K | -73.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 159.01M | 87.57M | 67.11M | 27.00M | 4.30M | 1.35M |
| Cost & Expenses | 160.61M | 88.53M | 69.18M | 27.00M | 4.30M | 1.35M |
| Interest Income | 10.34M | 3.50M | 36.00K | 188.00K | 40.00K | 0.00 |
| Interest Expense | 3.35M | 2.20M | 0.00 | 188.00K | 40.00K | 0.00 |
| Depreciation & Amortization | 877.00K | 789.00K | 606.00K | 246.00K | 74.00K | 1.00K |
| EBITDA | -131.67M | -59.11M | -13.17M | -26.56M | -4.56M | -1.35M |
| EBITDA Ratio | -754.69% | -229.03% | -18.55% | 0.00% | 0.00% | 0.00% |
| Operating Income | -143.16M | -62.71M | -12.16M | -27.00M | -4.30M | -1.35M |
| Operating Income Ratio | -820.53% | -242.92% | -21.32% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.27M | 617.00K | -1.62M | 188.00K | -371.00K | 32.00K |
| Income Before Tax | -135.89M | -62.10M | -13.77M | -26.81M | -4.67M | -1.32M |
| Income Before Tax Ratio | -778.89% | -240.53% | -24.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.00K | 55.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -135.89M | -62.09M | -13.83M | -26.81M | -4.67M | -1.32M |
| Net Income Ratio | -778.89% | -240.51% | -24.25% | 0.00% | 0.00% | 0.00% |
| EPS | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| EPS Diluted | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| Weighted Avg Shares Out | 29.38M | 24.62M | 20.55M | 20.32M | 19.51M | 4.29M |
| Weighted Avg Shares Out (Dil) | 29.38M | 24.62M | 20.55M | 20.32M | 19.51M | 4.29M |
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet
The consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants David Nakasone - Head, IR Bobby Azamian - Chairman & CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - CFO and...
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago.
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that...
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company's newly created Medical Organization Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company's newly created...
Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?
Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients' eyelids
Source: https://incomestatements.info
Category: Stock Reports